An interventional study of Psychological assessments in Amyotrophic Lateral Sclerosis, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies in Amyotrophic Lateral Sclerosis with a site in France — 28 open to participants now, 36 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · France.
Among the 132 studies in Amyotrophic Lateral Sclerosis with a site in France, this one is the 38th largest by planned enrollment of the 103 interventional ones that give a count, is one of 11 that started in 2023, is one of 47 with no phase, reaches primary completion later than 12 of the 35 other live ones, and was the 102nd registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →28 of the 132 studies in Amyotrophic Lateral Sclerosis with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–80
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Prilenia · Sites in France, United States, Belgium and 10 more countries
Ages 18–80
University Hospital, Bordeaux · Sites in France
Ages 18+ · Healthy volunteers
Zydus Therapeutics Inc. · Sites in France, United States, Australia and 9 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 27 · Phase 3 27
First in 1996; this study’s year is marked. 11 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 126 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 83 across the 103 interventional studies, 138 across the 29 observational. Of the 79 that completed or were terminated, 21 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 132 have an industry lead sponsor. The 10 most frequent:
Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
Assistance Publique Hopitaux De Marseille has 7 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
11 of the studies in Amyotrophic Lateral Sclerosis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT06249412Groupe Hospitalier du HavreThe Importance of Positive Expiratory Pressure Associated With the In-exsufflator in ALS Patients | 2026-12-01 |
| NCT05632757Assistance Publique Hopitaux De MarseilleAnticipated Patient and Caregiver Burden | 2026-12-22 |
| NCT05819931University Hospital, ToulouseBreathing With Amyotrophic Lateral Sclerosis | 2026-12-31 |
| NCT07091799University Hospital, BordeauxInterest of Measuring P2X4 Receptors on Blood Monocytes as a Diagnostic Marker in Amyotrophic Lateral Sclerosis: P2X4 as a Diagnostic Biomarker for ALS | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 132 studies in Amyotrophic Lateral Sclerosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Amyotrophic lateral sclerosis (ALS) is a degenerative neurological disease that causes progressive motor disability and is life threatening within a few years. The severity of the disease, the progressive loss of autonomy that leads to dependence on family and caregivers, and the lack of effective treatment sometimes leads patients to a loss of hope and to dark thoughts. The prevalence of suicidal ideation is high, with more than one third of people with ALS experiencing it. The psychological suffering of patients is often associated with that of their caregivers. The evaluation of the patients' feeling of being a burden has rarely been addressed in previous studies in ALS on the notion of burden. In this work, the investigators wish to evaluate the patient's ideas of death by also taking into account the caregiver's burden and the patient's feeling of being a burden. They wish to better understand this difficult experience by refocusing the study on the patient himself, which has rarely been addressed in studies on ALS and the notion of burden. By working on the caregiver's burden, both from the caregiver's point of view and as perceived by the patient, the investigators hope to find avenues of intervention and define actions that could help patients and their families and improve the quality of life of the patient-caregiver couple.
Inclusion Criteria (patient) :
Inclusion Criteria (caregiver) :
Exclusion Criteria (patient):
Exclusion Criteria (caregiver):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Psychological assessments
The visit will take place during a multidisciplinary assessment in the ALS Center at the Timone Hospital, Neuromuscular Disease and ALS Department. The patient will be accompanied by his/her caregiver. During this multidisciplinary assessment, the patient is present at the hospital between 8am and 4pm. The various scales and self-questionnaires can be completed during this time. The time required to complete these scales and self-questionnaires is estimated to be about 90 minutes.
Impact of the patient's sense of being a burden on the patient's suicidal ideation
Columbia scale (highest score meaning better outcome)
Time frame: Inclusion visit (month 0)
Relationship between the patient's feeling of being a burden living
Patient's Feelings of Burden Scale (highest score meaning worst outcome)
Time frame: Inclusion visit (month 0)
Relationship between the patient's reasons for living
Patient Reasons for Living Scale (highest score meaning worst outcome)
Time frame: Inclusion visit (month 0)
Relationship between the patient's feeling of being a burden and the caregiver's feeling of hardship
Patient's sense of burden scale and Zarit Caregiver Exertion Scale
Time frame: Inclusion visit (month 0)
Impact of the patient's sense of burden and the caregiver's sense of hardship on the quality of life of the patient and the caregiver
WHOQOL-Bref (World Health Organization Quality of Life, highest score meaning better outcome)
Time frame: Inclusion visit (month 0)
Relationship between the patient's feeling of being a burden and the motor disability
Beck scale (highest score meaning worse outcome)
Time frame: Inclusion visit (month 0)
Relationship between the patient's feeling of being a burden and the motor disability
Rankin scale (highest score meaning worse outcome)
Time frame: Inclusion visit (month 0)
Relationship between the patient's feeling of being a burden and the motor disability
ALSFRS score (highest score meaning better outcome)
Time frame: Inclusion visit (month 0)
Relationship between the depression of patient and the caregiver
Beck scale (highest score meaning worse outcome)
Time frame: Inclusion visit (month 0)
Relationship between the depression of patient and the caregiver
Rankin scale (highest score meaning worse outcome)
Time frame: Inclusion visit (month 0)
Relationship between the depression of patient and the caregiver
ALSFRS score (highest score meaning better outcome)
Time frame: Inclusion visit (month 0)
Impact of the caregiver's feeling of hardship on the patient's reasons for living
Patient Reasons for Living Scale (highest score meaning worst outcome)
Time frame: Inclusion visit (month 0)
Impact of the caregiver's feeling of hardship on the patient's reasons for living
Columbia Scale (highest score meaning better outcome)
Time frame: Inclusion visit (month 0)
Impact of the caregiver's feeling of hardship on the patient's and suicidal ideation
Patient Reasons for Living Scale (highest score meaning worst outcome)
Time frame: Inclusion visit (month 0)
Impact of the caregiver's feeling of hardship on the patient's and suicidal ideation
Columbia Scale (highest score meaning better outcome)
Time frame: Inclusion visit (month 0)
Relationship between the caregiver's perceived distress and the patient's suicidal ideation
Zarit scale (highest score meaning worse outcome)
Time frame: Inclusion visit (month 0)
Relationship between the caregiver's perceived distress and the patient's suicidal ideation
Columbia Scale (highest score meaning better outcome)
Time frame: Inclusion visit (month 0)
Relationship between caregiver's perceived distress and the patient's cognitive assessment
ECAS score (Cognitif Edinburgh Cognitive and Behavioural ALS Screen) (highest score meaning better outcome)
Time frame: Inclusion visit (month 0)
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.
Of 134 non-industry interventional studies with no phase under Amyotrophic Lateral Sclerosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 42 months is close to that.
Counting every sponsor, half of 154 studies reached it within 35 months; a quarter within 23 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
Assistance Publique Hopitaux De Marseille →